gray semaglutide Troubling Findings in Study of GLP-1 Compounders Medicare launches weight loss drug

Use of the LS-CAT Sector 21 was supported by the Michigan Economic Development Corporation and the Michigan Technology Tri-Corridor for the support of this research programme (Grant 085P1000817)

Interestingly, patients receiving semaglutide QW were more likely to be part of the commercial claim subgroup versus the Medicare claim subgroup, which suggests that the major differences in baseline characteristics observed were primarily driven by the commercial/Medicare ratio

Most good candidates have a BMI (body mass index) of 30 or greater with no serious weight-related conditions, but candidates with a BMI of 27 or more may also benefit from treatment if they have a weight-related condition

Drugs with three targets are also in the pipeline, including retatrutide, Lillys triple GLP-1, GIP and glucagon agonist combination